Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -16.72% is 38% below its 5-year average of -12.14%, near the low end of its 5-year range (-20.69%–-3.29%).
10.66% above its 12-month average of -18.71%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -4.07%.
RETURN ON ASSETS (ROA)
-16.72%
RETURN ON ASSETS (ROA) AVG TTM
-18.71%
RETURN ON ASSETS (ROA) AVG 3Y
-15.50%
RETURN ON ASSETS (ROA) AVG 5Y
-12.14%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+10.66%
CURRENT VS 3Y AVG
-7.89%
CURRENT VS 5Y AVG
-37.76%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-24.96%
median of 441 covered companies
CURRENT VS SECTOR MEDIAN
+33.01%
vs the sector median at left
GH Research PLC
Market Cap
$1.52B
Return on Assets (ROA)
-16.72%
TTM Avg
-18.71%
3Y Avg
-15.50%
5Y Avg
-12.14%
Market Cap
$1.52B
Return on Assets (ROA)
10.96%
TTM Avg
-5.00%
3Y Avg
-12.25%
5Y Avg
-27.07%
Market Cap
$1.51B
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.57B
Return on Assets (ROA)
-4.89%
TTM Avg
-0.43%
3Y Avg
-0.87%
5Y Avg
-1.37%
Market Cap
$1.46B
Return on Assets (ROA)
61.75%
TTM Avg
-16.82%
3Y Avg
-22.73%
5Y Avg
-17.45%
Market Cap
$1.45B
Return on Assets (ROA)
14.98%
TTM Avg
6.07%
3Y Avg
5.42%
5Y Avg
6.72%
Market Cap
$1.43B
Return on Assets (ROA)
-32.81%
TTM Avg
-32.81%
3Y Avg
-32.81%
5Y Avg
-32.81%
Market Cap
$1.65B
Return on Assets (ROA)
-13.91%
TTM Avg
-19.51%
3Y Avg
-22.81%
5Y Avg
-24.34%
Market Cap
$1.65B
Return on Assets (ROA)
7.08%
TTM Avg
2.00%
3Y Avg
-0.05%
5Y Avg
-1.77%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GH Research PLC (GHRS) | $1.52B | -16.72% | -18.71% | -15.50% | -12.14% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.52B | 10.96% | -5.00% | -12.25% | -27.07% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.51B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.57B | -4.89% | -0.43% | -0.87% | -1.37% |
| AnaptysBio, Inc. (ANAB)vs › | $1.46B | 61.75% | -16.82% | -22.73% | -17.45% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 14.98% | 6.07% | 5.42% | 6.72% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | -32.81% | -32.81% | -32.81% | -32.81% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | -13.91% | -19.51% | -22.81% | -24.34% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.65B | 7.08% | 2.00% | -0.05% | -1.77% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | -89.60% | 418.97% | 177.41% | 100.38% |
ROA
-16.7%
ROE
-17.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -16.74% |
| 2024-12-31 | -20.69% |
| 2023-12-31 | -15.73% |
| 2022-12-31 | -8.83% |
| 2021-12-31 | -3.29% |
| 2020-12-31 | -7.54% |
| 2019-12-31 | -61.51% |
